Inmune Stock Earnings Reports

INmune Bio reported Q3 2025 progress across its three platform programs and provided near-term regulatory and development milestones. CORDStrom (an MSC platform) is the lead program: INmune is preparing for a UK Marketing Authorization Application (MAA) targeted for mid-2026 with a subsequent U.S. BLA filing a few months later; technology transfer into CGMP manufacturing is complete and potency/assay work is underway. Clinical data from the UK MissionEB trial show reduced systemic itch and improvements in disease activity with a favorable safety profile; deeper independent statistical analyses are in progress. XPro (anti-neuroinflammation program for Alzheimer’s) has Phase II MINDFuL data submitted for peer review (preprint available), shows stronger effects in patients with higher baseline inflammation, and INmune is preparing for an end-of-Phase II meeting with FDA and pursuit of an accelerated pathway in early 2026. INKmune completed its Phase II component in castration-resistant prostate cancer, meeting the primary endpoint and 2 of 3 secondary endpoints; a randomized Phase II design is planned for 2026 as resources permit. Financials: Q3 net loss was ~$6.5M vs $12.1M year-ago; R&D spend fell to ~$4.9M; cash and equivalents were ~$27.7M at 9/30/25, which management estimates funds operations into Q4 2026. Key near-term catalysts: additional CORDStrom data in Q4 2025, UK MHRA scientific advice and MAA filing in mid-2026, BLA submission thereafter, MRI/imaging data and FDA alignment for XPro in early 2026. Risks: standard biotech risks remain (regulatory uncertainty, clinical confirmation, limited cash runway absent financing or partnerships).